ClinicalTrials.gg
CompletedNCT02417844Updated Apr 17, 2020Results posted

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

A Phase 1 interventional study of tamsulosin (Astellas) and Tamsulosin HCL in Prostatic Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-17.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
42nd of 48
34 · median 118
Started
2015
with 4 others
Phase 1
9 of 48
none open now
Registered
25th of 48
by date
Lead sponsor
5 of 48
Boehringer Ingelheim

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 42nd largest by enrollment, is one of 5 that started in 2015, is one of 9 in phase 1, and was the 25th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 64 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

Two tamsulosin HClformulations will be tested in fed state

03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Health male volunteers 18 years and older

Exclusion criteria

Exclusion criteria:

History of or allergy to IMP or its or any related medication

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    Tamsulosin HCl

    Drug: Tamsulosin HCL

  • Active comparator
    Tamsulosin

    Drug: tamsulosin (Astellas)

06

What researchers measure

Primary outcomes

  1. Maximum Measured Concentration (Cmax)

    Maximum measured concentration of analyte in plasma (Cmax)

    Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  2. Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)

    Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  3. Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)

    Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).

    Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

Secondary outcomes

  1. Time to Maximum Plasma Concentration (Tmax)

    Time from last dosing to the maximum plasma concentration (tmax).

    Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  2. Terminal Elimination Rate Constant (λz)

    Terminal elimination rate constant in plasma (λz)

    Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  3. Apparent Terminal Elimination Half-life (t1/2)

    Apparent terminal elimination half-life of the analyte in plasma (t1/2)

    Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

07

Results

Posted Apr 17, 2020

Participant flow

Participant flow — Overall Study
MilestoneTamsulosin HCl (Test) / Flomax Relief (Reference)Flomax Relief (Reference) / Tamsulosin HCl (Test)
Started1717
Completed1717
Not completed00

Outcome measures

PrimaryMaximum Measured Concentration (Cmax)

Maximum measured concentration of analyte in plasma (Cmax)

Time frame:
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · pg/mL
Maximum Measured Concentration (Cmax)
pg/mLTamsulosin HCl (Test)Flomax Relief (Reference)
Maximum Measured Concentration (Cmax)8826 ± 31.88856 ± 34.0
Statistical analysis
  • Tamsulosin HCl (Test) vs Flomax Relief (Reference) · Geometric mean ratio (%): 99.66 · 90% CI 92.19 to 107.74The standard deviation in the statistical analysis is actually the intra-individual coefficient of variation. Ratio calculated as test divided by reference.
PrimaryArea Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)

Time frame:
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · h*pg/mL
Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
h*pg/mLTamsulosin HCl (Test)Flomax Relief (Reference)
Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)164700 ± 42.4165400 ± 43.7
Statistical analysis
  • Tamsulosin HCl (Test) vs Flomax Relief (Reference) · Geometric mean ratio (%): 99.58 · 90% CI 94.23 to 105.24The standard deviation in the statistical analysis is actually the intra-individual coefficient of variation. Ratio calculated as test divided by reference.
PrimaryArea Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)

Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).

Time frame:
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · h*pg/mL
Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)
h*pg/mLTamsulosin HCl (Test)Flomax Relief (Reference)
Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)170100 ± 44.1171000 ± 45.2
Statistical analysis
  • Tamsulosin HCl (Test) vs Flomax Relief (Reference) · Geometric mean ratio (%): 99.48 · 90% CI 93.90 to 105.39The standard deviation in the statistical analysis is actually the intra-individual coefficient of variation. Ratio calculated as test divided by reference.
SecondaryTime to Maximum Plasma Concentration (Tmax)

Time from last dosing to the maximum plasma concentration (tmax).

Time frame:
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax)
HoursTamsulosin HCl (Test)Flomax Relief (Reference)
Time to Maximum Plasma Concentration (Tmax)7.51 (4.00 to 12.01)8.00 (4.00 to 24.01)
SecondaryTerminal Elimination Rate Constant (λz)

Terminal elimination rate constant in plasma (λz)

Time frame:
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · 1/hour
Terminal Elimination Rate Constant (λz)
1/hourTamsulosin HCl (Test)Flomax Relief (Reference)
Terminal Elimination Rate Constant (λz)0.05 ± 21.60.05 ± 21.9
SecondaryApparent Terminal Elimination Half-life (t1/2)

Apparent terminal elimination half-life of the analyte in plasma (t1/2)

Time frame:
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · hours
Apparent Terminal Elimination Half-life (t1/2)
hoursTamsulosin HCl (Test)Flomax Relief (Reference)
Apparent Terminal Elimination Half-life (t1/2)13.16 ± 21.613.21 ± 21.9

Adverse events

Collected over Up to 72 hours. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tamsulosin HCl (Test)—0/34 (0%)5/34 (14.7%)
Flomax Relief (Reference)—0/34 (0%)1/34 (2.9%)
Most frequent other events
Most frequent other events
EventTamsulosin HCl (Test)Flomax Relief (Reference)
HeadacheNervous system disorders5/341/34

Baseline characteristics

Treated set which included all subjects who received at least one dose of investigational medicinal product.

Age, Continuous
Age, Continuous(Years)All Subjects
Mean24.6 ± 5.53
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female0
Male34
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2020, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2015
First posted
Apr 16, 2015
Start
Apr 2015
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Apr 17, 2020
Last update
Apr 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02417844
Responsible party
Sponsor
First posted
Apr 16, 2015
Start date
Apr 2015
Primary completion
May 2015
Completion
May 2015
Results posted
Apr 17, 2020
Last update
Apr 17, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion